Proven efficacy and tolerability

Flebogamma® DIF has been shown to be an effective and well-tolerated treatment for primary immunodeficiency and autoimmune disease.1-4

Flebogamma® DIF is an intravenous immune globulin (IVIG) (human), indicated for5:

  • Replacement therapy in adults, children, and adolescents (2-18 years) in:
    • Primary immunodeficiency syndromes with impaired antibody production
    • Hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia in whom prophylactic antibiotics have failed
    • Hypogammaglobulinaemia and recurrent bacterial infections in plateau phase multiple myeloma patients who failed to respond to pneumococcal immunization
    • Hypogammaglobulinaemia in patients after allogenic haematopoietic stem cell transplantation (HSCT)
    • Congenital AIDS with recurrent bacterial infections
  • Immunomodulation in adults, children, and adolescents (2-18 years) in:
    • Primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count
    • Guillain-Barré syndrome
    • Kawasaki disease

about-2-pic [M05]

Flebogamma® DIF is DIFferent from other IVIGs

Flebogamma DIF bottle

Product characteristics

The unique properties of Flebogamma® DIF distinguish it from other IVIG products.

Learn more >

Two patients man and woman

Broad spectrum of antibodies

The antibody composition of Flebogamma® DIF protects your patients against a wide range of pathogens.

Learn more >

Doctor with Patient and Laptop

Personalised dosing

Flebogamma® DIF provides the flexibility to treat your patients like the individuals they are.

Learn more >



  1. Berger M, Flebogamma 5% DIF Investigators. A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma 5% DIF, the next generation of Flebogamma. J Clin Immunol. 2007;27(6):628-633.
  2. Berger M, Pinciaro PJ, Althaus A, et al. Efficacy, pharmacokinetics, safety, and tolerability of Flebogamma 10% DIF, a high-purity human intravenous immunoglobulin, in primary immunodeficiency. J Clin Immunol. 2010;30(2):321-329.
  3. Julia A, Kovaleva L, Loria S, et al. Clinical efficacy and safety of Flebogamma DIF, a new high-purity human intravenous immunoglobulin, in adult patients with chronic idiopathic thrombocytopenic purpura. Transfus Med. 2009;19(5):260-268.
  4. Kovaleva L, Apte S, Damodar S, et al. Safety and efficacy of a 10% intravenous immunoglobulin preparation in patients with immune thrombocytopenic purpura: results of two international, multicenter studies. Immunotherapy. 2016;8(12):1371-1381.
  5. Flebogamma® DIF EU SmPC.